Lantern Pharma(LTRN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates ● Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. ● Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort. ● Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma's drug ...